Abnormal processing of immune complexes (IC) may be important in the pathogenesis of systemic lupus erythematosus (SLE). The clearance of large soluble IC (comprising hepatitis B surface antigen (HBsAg)/anti-HBsAg) radiolabeled with "23I was examined in 12 normal subjects and 10 patients with SLE. IC localization was analyzed by static and dynamic gamma-scintigraphy. Initial IC clearance from blood was more rapid in patients (median 11/2 = 2.15 min) than normals (median t1/2 = 5.15 min) due to more rapid uptake in the liver. However, in the SLE group, up to 12% of complexes were released from the liver after 30-50 min. Splenic uptake of immune complexes was reduced in the patients and there was reduced ability to retain IC in this organ. Plasma complement levels and erythrocyte complement receptor type 1 numbers were reduced in the patients, resulting in defective opsonization of IC and reduced red cell binding in vivo. These observations support the hypothesis that IC handling is abnormal in SLE. (J. Clin.
Introduction
There are several ways in which abnormal processing of immune complexes (IC)' may play a role in the pathogenesis of systemic lupus erythematosus (SLE). Immune complexes may escape clearance and catabolism by the mononuclear phagocytic system (MPS) because ofabnormal transport or presentation mechanisms (1) . Furthermore, there may be defects in MPS function in patients with SLE, and hypotheses to explain these have included "saturation" by immune complexes (2) and intrinsic abnormalities of phagocytic cell function (3) .
Studies in vivo in primates have delineated the mechanism of clearance from the circulation of soluble immune complexes. In baboons, IgG-containing immune complexes fixed complement, bound to complement receptor type 1 (CR1 ) on erythrocytes and were transported to the fixed mononuclear phagocytic system where they were cleared from the circulation (4) . Several investigators have used soluble immune complexes or aggregated IgG to study the clearance pattern of immune complexes from the circulation of humans (5) (6) (7) (8) (9) . Abnormally fast clearance of immune complexes in patients with SLE was observed and correlated with hypocomplementemia (7) . These studies were performed using '25I-labeled immune complexes and it was not possible to ascertain the site of rapid clearance of immune complexes. Imaging studies performed using heat-aggregated IgG showed accelerated uptake in the liver (10) .
We describe here the results ofexperiments using '231-hepatitis B surface antigen-containing immune complexes to track the fate of immune complexes in normal humans and patients with SLE. Several abnormalities of immune complex kinetics were identified in patients with SLE, hypocomplementemia, and low CR1 numbers. These were accelerated clearance of immune complexes in the liver, impaired retention of complexes within the liver with release of complexes back to the circulation, and impaired immune complex clearance by the spleen.
Methods
Subjects 26 subjects were studied, 18 female and 8 males. 12 normal volunteers were recruited from the laboratory staff, aged from 23 to 59 yr, 6 female and 6 male. Four additional normal subjects (three female, one male) received radiolabeled antigen alone. The patients were 10 subjects with SLE, aged from 21 to 56 yr, 9 females and 1 male, all ofwhom fulfilled the revised ARA criteria for this disease. At the time of the study, 8 of the 10 patients had clinically active disease involving more than one organ system, with an erythrocyte sedimentation rate > 40 mm in the first hour in all cases, and a C4 < 50% normal human serum pool, elevated DNA binding (> 30% by Farr assay), or both. Two patients were studied on two occasions. Fully informed consent was obtained from all the participants for the study, which was approved by the Hammersmith Hospital Ethics committee and the Administration of Radioactive Substances Advisory Committee (ARSAC).
All subjects received 120 mg twice daily oforal potassium iodide for 36 h before each study and a further 48 h after injection to block thyroid uptake of 123I.
Hepatitis B surface antigen (HBsAg) This was a gift from Dr. J. A. Schifferli (H6pital Cantonale, Geneva, Switzerland). The antigen was in the form ofa large polymeric protein (molecular mass around 3,000 kD) and was pyrogen free. It has been previously characterized both in vitro and in vivo (11) . 30 ,g antigen was used for the preparation of each batch of IC.
Anti-HBsAg antibody
Polyclonal antiserum to HBsAg was also a gift from Dr. Schifferli (Croix-Rouge, Bern, Switzerland). One vial of sterile lyophilized immunoglobulin (> 95% IgGi ) was dissolved in 10 ml sterile water (Antigen, UK), to produce a final concentration of 50 U/ml, immediately before IC preparation.
Radiolabeling ofHBsAg
The antigen was labeled with 123I (Medgenex, Brussels, Belgium), using N-bromosuccinamide ( 12) , to a high specific activity (25-30 JLCi/Mg). 30 1Ag of antigen was labeled immediately before each study; free and bound iodine were separated on a sterile G25 column preblocked with sterile human albumin. The 123I was > 97% protein bound in the final preparation in all cases.
IC preparation HBsAg/anti-HBsAg IC were prepared as follows: 30 ,g ofradiolabeled HBsAg was incubated with 10 ml ofantiserum for 60 min at 370C. This corresponds to a fivefold antibody excess. Two 5-ml samples were then drawn into syringes, and the total radioactivity in each dose measured using a radioisotope calibrator (ARC 120, Capintec; Amersham, Amersham, UK). An IC mixture containing 15g of antigen was used for each subject, with an activity ofbetween 300 and 500 MCi. For each batch of labeled IC prepared, one patient and one normal control were studied in parallel.
Injection and imaging protocol
An intravenous cannula was inserted into the subject's left antecubital fossa for injection of labeled IC and into a similar line in the right arm for blood sampling. 5 ml of IC was injected as a rapid bolus at time 0, with the patient positioned over a gamma-camera (IGE 400T on-line to an MDS A2 computer). Dynamic imaging was performed (serial 20s frames) for 50 min, followed by 5-min anterior and posterior static imaging at 1, 4, and 24 h. Four subjects underwent dynamic scanning for 2 h, and whole-body scanning was also performed in two cases, using a Starcam (IGE) gamma camera.
Blood samples
Preinjection serum and erythrocytes were obtained from all subjects for the estimation of serum complement levels and red cell CR1 numbers. Postinjection, 6- 
Results

Studies with HBsAg alone
Control experiments were performed to characterize the clearance pattern ofthe HBsAg when injected alone. 15 Mg of 123I-labeled antigen was injected into two immune and two nonimmune normal volunteers. Localization of antigen to the liver and spleen occurred in all cases, maximum uptake in the liver occurring after 22 and 24 min, and 28 and 35 min in the immune and nonimmune subjects, respectively. Splenic uptake of radioactivity at 1 h was between 4 and 7.5% of the injected dose in the four subjects studied, and there was no difference between immune and nonimmune individuals. However, more rapid splenic localization occurred in the immune (mean t1/2= 9 min) than in the nonimmune subjects (mean t,/2 = 21 min). Less than 2% of circulating activity was measured on erythrocytes in the nonimmune subjects whereas 12 and 14% binding was observed in the immune controls. Maximum binding in the immune subjects occurred between 5 and 10 min, much less rapidly than in those patients injected with preformed IC (see below).
IC imaging studies
Initial IC clearance and localization. In SLE patients and controls there was uptake of IC in the liver and spleen, with rapid clearance from the blood (Fig. 1 a) . Scanning over the lungs, kidneys, and other organs revealed no specific uptake above blood pool level in either group (Fig. 1 b) . (Fig. 3 B) .
Immune Measurement of sequential whole blood, protein-bound, and red cell-bound activity after injection of IC indicated that significant release ofprotein-bound radioactivity from the liver was occurring in the patient group after 30-40 min. Typical data are shown in Fig. 4 , in which the patterns ofIC handling in a normal subject and an SLE patient are compared. TCA precipitation data (Fig. 3 A) (Fig. 7 a) . The ability of the spleen to retain ICs after initial uptake into the organ was also abnormal among the SLE patients. The activity remaining in the spleen at 24 h after injection was expressed as a percentage of the maximum organ uptake measured during the first hour after injection of the ICs. Among the SLE patients median uptake was 39% maximum (range: 24-52%) compared with normal subjects (median, 65.5%; range, 58-73%) (U = 0, P < 0.002) (Fig. 7 b) . It was not possible to track the localization of IC for > 24 h because of the short half-life of 1231.
Factors influencing clearance pattern in normals and patients The main differences between the control subjects and patients with SLE were as follows: (a) initial IC clearance was more rapid in patients than in normals, as complexes localized in the liver, (b) IC release from the liver occurred subsequently in patients; and (c) there was significantly reduced splenic complex uptake in the patient group. The possible factors contributing to these differences were explored:
Hypocomplementemia and IC size. Among the 10 subjects with SLE there was a close correlation between the level of C4 in the plasma and the t112 of IC clearance, rsp = 0.997 (Fig. 8) .
There was also a correlation between plasma C3 and the t,2 of Patients studied on two occasions Two patients with SLE were studied twice, at intervals of 8 and 9 mo, respectively. Both had been treated with corticosteroids and azathioprine during the interim period, with clinical and serologic improvement manifest by a rise in C4 and a fall in DNA binding (see Table I ). CR1 numbers on erythrocytes rose by only 14 and 12 molecules per cell, respectively. The measured t112, time for 90% liver uptake, and percentage hepatic and splenic uptake data are shown in Table I . In both subjects a rise in C4 correlated with an increased clearance time and reduced hepatic uptake, with correspondingly greater splenic localization ofcomplexes. IC release into the circulation between 30 and 60 min occurred but was reduced in the second set of studies.
Discussion
The use of '23I-labeled soluble immune complexes offers the opportunity for the analysis of the physiological mechanisms Time after injection (min) Figure 4 . Radioactivity measured sequentially in blood after IC injection, whole blood, TCA-precipitable, and RBC-bound activity, comparison between a typical normal I and a patient. There was more rapid 60 70 clearance of IC in patients, with reduced binding to erythrocyte CR 1.
of immune complex clearance from the circulation in humans and how these may be perturbed in disease. We found three main differences between the clearance pattern of immune complexes in normal subjects and patients with SLE. Clearance of immune complexes by the liver was faster in patients with SLE than in controls (the opposite result to that previously observed for clearance of IgG-coated erythrocytes by the spleen [3] ), and the increased clearance rate correlated with hypocomplementemia and reduced erythrocyte CR1 numbers. The second difference was that uptake and internalization of immune complexes by the MPS of the liver was abnormal in patients with SLE; up to 12% ofthe injected HBsAg, still com- plexed with antibody, was released back into the circulation from the liver, a phenomenon not seen in normal control subjects. The third difference was that there was much reduced IC uptake in the spleen in the patients compared with controls. We performed preliminary experiments to study the clearance of labeled antigen alone in immune and nonimmune subjects and the results were similar to those obtained previously by Madi et al. ( 11) . Antigen cleared in both liver and spleen but with kinetics much slower than those of IC. Maximum in vivo binding of nascent IC to erythrocyte CR1 in immune subjects was 14%, similar both to that measured by Madi et al. ( 11 ) and that observed in our previous study ofin vivo IC formation and clearance in patients receiving radioimmunotherapy ( 19) .
Three interrelated factors appeared to be important in determining the faster clearance and localization of immune complexes in the liver in patients compared with normal subjects. These were hypocomplementemia, large IC size, and reduced binding to erythrocyte CR1, each of which was associated with increased rate of uptake of immune complexes by the liver. A close correlation was observed between the level of the classical pathway component C4 and the initial rate of IC clearance. The results ofprevious work in vitro (20) (21) (22) and in vivo (7) implied that low levels ofcomplement might have two main effects on complex processing. Firstly, IC size would be expected to be greater due to defective complex solubilization (21, 22) . This was confirmed in the present study on six occasions using sucrose density gradient analysis. Secondly, defective coating of immune complexes with complement would reduce binding to CR1 on erythrocytes. CR1 numbers on the erythrocytes of patients with active SLE are significantly lower than in normal controls ( 15, (23) (24) (25) . This was also the case in the present study, and low levels of erythrocyte CR1 correlated closely with reduced IC binding to erythrocytes.
The scanning results showed release of 1231I counts from the liver during the first 60 min among the SLE patients, which was not seen in normal subjects. Two possible explanations for this observation are faster internalization and catabolism of complexes in the SLE patients followed by early release of free '23I size between antigen and injected ICs.
the form of immune complexes because they bound to Staphylococcal protein A, which only bound the '23I-HBsAg when complexed with antibody; and (c) the size ofthe released material was -30 S when analyzed by sucrose density centrifugation. In contrast, there was evidence that uptake and processing of immune complexes in both liver and spleen, with consequent release of free i23I, was more efficient among the normal control subjects (Fig. 3 ).
There is a precedent for these results from experiments on clearance mechanisms of immune complexes in mice with SLE-like disease. The clearance of cross-linked mouse anti-DNP oligomers was studied in NZB/W and control mice, both in vivo (26) and in isolated perfused livers (27) . Immune complexes were cleared in vivo mainly in the liver, 76% of the injected label localized to the liver at 1 h. Initial clearance from the circulation was more rapid in the NZB/W F1 lupus mice than in control mice (26) , analogous to the observations reported in the present study. The early stages of IC uptake were examined by perfusing isolated murine livers via the portal vein with labeled immune complexes. There was initially enhanced hepatic uptake in the autoimmune mice compared with controls. However, the complexes in the NZB and NZB/ W F1 lupus mice could be readily displaced by saturating doses of heat-aggregated human y-globulin, suggesting impaired binding to Kupffer cells and defective phagocytosis (27) , similar to that postulated in the present study.
The pathway of IC clearance in nonhuman primates has been established in baboons and chimpanzees (4, 6, 28) . Large immune complexes injected into the circulation bound efficiently to erythrocytes and were cleared in the liver. Blocking experiments using monoclonal anti-FcyIII in chimpanzees showed that these receptors were involved in hepatic clearance of soluble anti-dsDNA/dsDNA ICs (28) . Maximal blockade ofIC uptake by the liver was observed with IC fractions that did not bind to erythrocytes and had presumably bound less C3b. We previously studied the clearance mechanisms in humans of 251I-soluble tetanus toxoid (TT)/antitetanus toxoid complexes (7, 8) and found that complexes were cleared from the circulation more rapidly in patients with SLE and/or hypocomplementemia than in normal subjects. The ance ofthese complexes was not ascertained and we interpreted the very fast clearance rate of complexes to be due to trapping ofICs outside the MPS, possibly in the pulmonary vasculature. This interpretation was probably incorrect in the light of the present data. Other studies have also shown IC clearance to be abnormally fast in patients with SLE, notably a recent study by Madi et al. (9), using similar HBsAg/anti-HBsAg complexes to those in the present study, in which the clearance sites ofthe immune complexes were not visualized. Another model for the study of IC clearance is the use of aggregated IgG (A-IgG) (6, 10). Halma et al. (10) reported abnormally rapid initial A-IgG clearance by the liver in patients with SLE and decreased maximum splenic uptake, but there were no correlations observed between E-CR 1 and A-IgG binding to erythrocytes or between complement levels and elimination kinetics.
It is of some interest to contrast the present findings with the results of analyses of MPS function using IgG-or complement-coated erythrocytes as probes. Erythrocytes coated with anti-rhesus IgG, which did not fix complement, were mainly removed from the circulation in the spleen, clearance mediated by Fc receptors (34, 35). In contrast, erythrocytes coated with IgM and C3 are retained transiently in the liver by ligation of C3 receptors (34, 36, 37). Catabolism ofthe C3 on the erythrocytes to C3dg was accompanied by their release back to the circulation. We do not have precise data on the ratio ofimmunoglobulin to C3 on our immune complexes, as these parameters changed quickly in vivo after IC injection (illustrated in Fig. 6 b, which shows the changes in IC size after injection). However, up The third major difference in immune complex processing between normal subjects and patients with SLE observed in this study related to the uptake of IC in the spleen. At 1 h after injection only -10% of injected IC were present in the spleen in the patients compared with one quarter in the normals, suggesting preferential uptake. in the liver and reduced initial splenic localization. We also found that antigen was retained much more efficiently in the spleen in the normals than in the hypocomplementemic subjects: 15-20% injected activity was still measurable in the spleen at 24 h in normals compared with 3-5% in patients. The splenic clearance of IgG-coated erythrocytes has also been shown to be abnormal in patients with SLE, as discussed above, although early work suggested a correlation between tl 2 of E-IgG clearance and disease activity (3, 38) , later studies have failed to confirm these observations ( 35, 40) . The uptake of radiolabeled A-IgG by the spleen has also been shown previously to be reduced in SLE patients (5) . The anatomical organization of the spleen is ideally suited to the processing oferythrocytes, particulate antigens, and opsonized immune complexes delivered on erythrocytes bound to CR 1. The splenic red pulp has a complex and highly specialized vasculature organized in a reticular mesh that functions as a filtration bed (41) . Plasma and cells are progressively separated as blood passes through the organ, resulting in a relatively elevated hematocrit in the red pulp, an environment suited to the interaction of opsonized IC bound to red cell CR1 and the periarterial macrophages. Hypocomplementemia, and reduced erythrocyte CR1 result in defective opsonization of IC and much reduced binding to erythrocytes. We hypothesize that it is abnormal delivery of IC to the mononuclear phagocytic system that results in reduced initial uptake and impaired complex retention in the spleen. A parallel may be drawn between these results and experiments demonstrating the importance of the complement system in determining the binding of immune complexes to follicular dendritic cells (42) (43) (44) , a process important in the generation ofmemory B lymphocytes. We speculate that hypocomplementemia and abnormal processing of immune complexes may be associated with abnormal pathways of antigen processing and presentation and that this may be a factor in promoting the autoimmune response in SLE.
In conclusion, we have presented evidence that the clearance pathway of large soluble immune complexes from the circulation in patients with SLE is abnormal and, in particular, that hepatic processing of immune complexes is impaired. There was reduced uptake ofimmune complexes in the spleen. These abnormalities may play a role in the immunopathogenesis of the disease by allowing immune complex deposition in tissues outside the MPS and, speculatively, by promoting abnormal pathways of antigen presentation.
